Zoruxa 5 mg/100 ml (100 ml)

Indication

Treatment of osteoporosis in post-menopausal women and in adult men at increased risk of fracture (including after a recent low-trauma hip fracture), osteoporosis associated with long-term glucocorticoid therapy, and Paget's disease of bone in adults.

Ingredients

• Zoledronic acid (as monohydrate) 5 mg per 100 ml

Direction

For intravenous infusion only by a healthcare professional; not for direct injection. Osteoporosis: a single 5 mg infusion once a year, given over at least 15 minutes. Paget's disease: a single 5 mg infusion. Patients should be well hydrated before infusion and receive adequate calcium and vitamin D. Do not mix with calcium-containing infusion solutions.

Side effects

• Flu
• like symptoms after infusion: fever
• muscle or joint pain
• headache
• tiredness
• Nausea
• Low blood calcium
• Rarely kidney problems
• osteonecrosis of the jaw or atypical femur fractures
• Consult a doctor or pharmacist before use
• and stop use and seek advice if an allergic reaction or unusual symptoms occur.

Precautions

• Prescription medicine for hospital/clinic use
• do not exceed the prescribed dose
• Do not use if creatinine clearance is below 35 ml/min
• in hypocalcaemia
• pregnancy or breastfeeding
• Correct low calcium before treatment and keep good dental hygiene
• report jaw
• thigh or hip pain
• Do not mix with calcium
• containing infusion solutions
• not for direct injection
• Consult a doctor or pharmacist before use
• and stop use and seek advice if an allergic reaction or unusual symptoms occur.